Clinical trials: Capsule Opacification
Cataract
Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular Lenses
The purpose of this study is to assess and compare visual outcomes of the AcrySof® IQ ReSTOR® +3.0 D intraocular lens (IOL) to a commercially available monofocal IOL in cataract patients.
- Trial name
- NCT01290068
- Testing
- AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL, AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL, Monofocal IOL
- Volunteers
- 208 people
- Sponsor
- Alcon Research
Cataract
Optimizing the Assessment of Refractive Outcomes After Cataract Surgery
The purpose of this study is to evaluate current available assessments (automated vs. manual) with which manifest refraction data and biometric variables are obtained to understand if data from an automated refractor can be…
- Trial name
- NCT02842151
- Testing
- Manifest refraction, ACRYSOF® IQ Monofocal IOL Model SN60WF, Topcon® KR-1W Wave-Front Analyzer
- Volunteers
- 162 people
- Sponsor
- Alcon Research
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02089113
- Testing
- Dexamethasone
- Volunteers
- 241 people
- Sponsor
- Ocular Therapeutix, Inc.
Ocular Inflammation and Pain
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone…
- Trial name
- NCT01666210
- Testing
- OTX-DP (Dexamethasone punctum plug)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ocular Therapeutix, Inc.
Ocular Inflammation and Pain After Cataract Surgery
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04810962
- Testing
- APP13007, 0.05%
- Where
- 31 sites in United States
- Volunteers
- 370 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Posterior Capsule Opacification, Ocular Hypertension
Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy
To compare the efficacy of a Brinzolamide/Brimonidine fixed combination (FC) with Brimonidine 0.2% in preventing intraocular pressure (IOP) elevations after neodymium: yttrium-aluminum-garnet (Nd:YAG) laser posterior capsulotomy.
- Trial name
- NCT03192826
- Testing
- Brinzolamide/Brimonidine FC, Brimonidine 0.2%, Artificial tears
- Where
- Greece
- Volunteers
- 79 people
- Sponsor
- University Hospital of Patras
Pain, Inflammation
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two…
- Trial name
- NCT03496467
- Testing
- Nepafenac PPDS
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mati Therapeutics Inc.
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Ocular Inflammation and Pain
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04739709
- Testing
- APP13007, 0.05%
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 378 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Ocular Discomfort
A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.
- Trial name
- NCT03035864
- Testing
- rhNGF, Vehicle
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Dompé Farmaceutici S.p.A
Corneal Edema After Cataract Surgery
A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
The purpose of this study is to assess the safety and efficacy of K-321 in subjects after cataract surgery
- Trial name
- NCT05528172
- Testing
- Ripasudil
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 330 people
- Sponsor
- Kowa Research Institute, Inc.
Cataract
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
- Trial name
- NCT01605942
- Testing
- Dexamethasone Drug Delivery System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Allergan
Cataract
Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens
To assess posterior capsule opacification (PCO) in patients implanted with either the AcrySof SN60AT lens or the AcrySof SN60WF lens.
- Trial name
- NCT00762021
- Testing
- SN60AT, SN60WF
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Alcon Research
Cataract, After Cataract
Autonomous Telephone Follow-up After Cataract Surgery
This project will apply AI technology to meet the gap between increasing demand and limited capacity of high- volume healthcare services.
- Trial name
- NCT05213390
- Testing
- Dora
- Where
- 2 sites in United Kingdom
- Volunteers
- 225 people
- Sponsor
- University of Plymouth
Macular Edema
A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
The purpose of this study is to determine whether nepafenac is safe and effective for reducing the incidence of macular edema following cataract surgery in diabetic retinopathy patients.
- Trial name
- NCT00782717
- Testing
- Nepafenac ophthalmic suspension, 0.1% (NEVANAC), Nepafenac ophthalmic suspension vehicle, Prednisolone acetate ophthalmic suspension (OMNIPRED)
- Volunteers
- 263 people
- Sponsor
- Alcon Research
Dry Eye Syndromes
Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery
The purpose of this study is determine whether 3% diquafosol and 0.1% sodium hyaluronate are effective and safe in the treatment of patients with dry eye after cataract surgery.
- Trial name
- NCT02608489
- Testing
- Diquafosol (Diquas), Sodium Hyaluronate (Hyalein)
- Volunteers
- 86 people
- Sponsor
- Soonchunhyang University Hospital
Low Vision, Age Related Macular Degeneration
Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
This early feasibility study aims to improve near vision in subjects 55 years or older who have a clinical diagnosis of Age-Related Macular Degeneration.
- Trial name
- NCT04984590
- Testing
- IOPCL AMD MAG
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- OnPoint Vision Inc
Posterior Capsule Opacification, Retinal Degeneration
Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification
It has been hypothesized that potential effects of laser Nd: YAG laser posterior capsulotomy may affect macular pigment as well as choroidal thickness, macular thickness and anterior chamber parameters, so it was aimed to…
- Conditions
- Posterior Capsule Opacification, Retinal Degeneration, Retinal Detachment, Anterior Chamber Angle Congestion
- Trial name
- NCT03321253
- Testing
- Nd: YAG laser posterior capsulotomy
- Volunteers
- 38 people
- Sponsor
- Afyon Kocatepe University Hospital
Capsule Opacification, Pseudophakia
Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF
Age-related cataract is the main cause of impaired vision in the elderly population worldwide. In the UK, more than half of people who are over 65 have some cataract development in one or both eyes.
- Conditions
- Capsule Opacification, Pseudophakia, Cataract
- Trial name
- NCT01732484
- Testing
- intraocular lens implantation
- Volunteers
- 100 people
- Sponsor
- Medical University of Vienna
Cataract
Anterior Capsule Polishing Effect on Effective Lens Position
The purpose of this study is to evaluate effects of anterior capsule polishing on effective lens position (ELP) and actual axial movement of the intraocular lens (IOL) by measuring anterior chamber depth (ACD) patients with…
- Trial name
- NCT01598428
- Testing
- anterior capsule polishing
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shandong University